Sudden Arrhythmia Death Syndromes Foundation (SADS) Educates FDA on Living with ARVC/D Through Externally-Led Patient-Focused Drug Development Meeting
source: shutterstock.com

Sudden Arrhythmia Death Syndromes Foundation (SADS) Educates FDA on Living with ARVC/D Through Externally-Led Patient-Focused Drug Development Meeting

This press release was provided by the Sudden Arrhythmia Death Syndrome Foundation (SADS), a Patient Worthy partner organization. Key facts: ● Externally-led patient-focused drug development meeting (EL-PFDD) with FDA hosted…

Continue Reading Sudden Arrhythmia Death Syndromes Foundation (SADS) Educates FDA on Living with ARVC/D Through Externally-Led Patient-Focused Drug Development Meeting
OI Has Led to More Than 82 Broken Bones for This 6-Year-Old
Chronic osteomyelitis in the clavicle. Sourced from: Shannonpercivalsmith / CC BY (https://creativecommons.org/licenses/by/3.0)

OI Has Led to More Than 82 Broken Bones for This 6-Year-Old

For many people, a broken bone would severely interrupt their life. But six-year-old Avery Balcazar has learned to live with it—even when it’s tough. As reported by CBC News, Balcazar…

Continue Reading OI Has Led to More Than 82 Broken Bones for This 6-Year-Old
Rare Community Profiles: Fiercely Advocating for the SMA Community: Why Amanda Will Never Stop Fighting for her Son Kayden
Photo courtesy of Amanda Chaffin

Rare Community Profiles: Fiercely Advocating for the SMA Community: Why Amanda Will Never Stop Fighting for her Son Kayden

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: Fiercely Advocating for the SMA Community: Why Amanda Will Never Stop Fighting for her Son Kayden
Global Registries Could Change the Lives of Hundreds of Millions of Rare Disease Patients Everywhere
Photo courtesy of IndoUSRare

Global Registries Could Change the Lives of Hundreds of Millions of Rare Disease Patients Everywhere

Authored by Dr. Harsha Rajasimha, Founder and Executive Chairman, IndoUSrare. Co-Authored by Dr. Padma Rammoorthy, Medical Consultant, IndoUSrare. The diagnostic journey for patients with rare diseases often becomes a prolonged odyssey,…

Continue Reading Global Registries Could Change the Lives of Hundreds of Millions of Rare Disease Patients Everywhere
Do Cross-Over Arms in Clinical Oncology Trials Benefit Patients?
source: shutterstock.com

Do Cross-Over Arms in Clinical Oncology Trials Benefit Patients?

The Cholangiocarcinoma Foundation has recently released a white paper titled “Cross-over arms in oncology clinical trials: An important consideration for patients.” This paper highlights a non-traditional clinical trial approach that…

Continue Reading Do Cross-Over Arms in Clinical Oncology Trials Benefit Patients?

CB-010 Shows Promise for B-Cell Non-Hodgkin Lymphoma, Study Shows

Recent results are available from the dose escalation portion of the Phase 1 ANTLER study. In reporting from Targeted Oncology, Jordyn Sava shares that the study included 16 participants living…

Continue Reading CB-010 Shows Promise for B-Cell Non-Hodgkin Lymphoma, Study Shows
Mavorixafor is Safe and Effective for Treating WHIM Syndrome, Trial Data Suggests
JerzyGorecki / Pixabay

Mavorixafor is Safe and Effective for Treating WHIM Syndrome, Trial Data Suggests

  In the past, treatment for WHIM syndrome has focused on symptom management: treating infections and myelokathexis with antibiotics or granulocyte colony stimulating factor. Infusion can treat hypogammaglobulinemia and surgery…

Continue Reading Mavorixafor is Safe and Effective for Treating WHIM Syndrome, Trial Data Suggests
Positive Results in Phase 3 Chronic Inflammatory Demyelinating Polyneuropathy Trial
source: shutterstock.com

Positive Results in Phase 3 Chronic Inflammatory Demyelinating Polyneuropathy Trial

According to a story from Business Wire, the pharmaceutical company Takeda recently presented results from its phase 3 clinical trial evaluating HYQVIA (Human Immune Globulin Infusion 10% with Recombinant Human…

Continue Reading Positive Results in Phase 3 Chronic Inflammatory Demyelinating Polyneuropathy Trial